FDA-approved profile

PowerLook® Tomo Detection Software

iCAD Inc · Mammography/DBT · FDA-approved (PMA)

Concurrent computer-aided detection for radiologists interpreting compatible GE Senoclaire breast tomosynthesis examinations, with detected soft-tissue densities blended into the synthetic two-dimensional mammography image.

Clinical role
Concurrent computer-aided detection during DBT interpretation.
Images and patients
Mammography/DBT · Breast
Key limitation
The software is limited to compatible DBT systems and concurrent radiologist use; detections must be confirmed or dismissed by the interpreting physician.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyMammography/DBT · Breast
  • Workflow roleConcurrent computer-aided detection during DBT interpretation.
  • Required inputCompatible GE Senoclaire digital breast tomosynthesis image data.
  • Output and human actionA CAD-enhanced synthetic two-dimensional image with detected soft-tissue densities blended for concurrent radiologist review and navigation to corresponding DBT planes.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Concurrent computer-aided detection for radiologists interpreting compatible GE Senoclaire breast tomosynthesis examinations, with detected soft-tissue densities blended into the synthetic two-dimensional mammography image.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Concurrent computer-aided detection during DBT interpretation.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Compatible GE Senoclaire digital breast tomosynthesis image data.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
A CAD-enhanced synthetic two-dimensional image with detected soft-tissue densities blended for concurrent radiologist review and navigation to corresponding DBT planes.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Breast-imaging practices performing diagnostic interpretation of compatible DBT examinations.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Radiologists interpreting compatible GE Senoclaire breast tomosynthesis examinations.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The software is limited to compatible DBT systems and concurrent radiologist use; detections must be confirmed or dismissed by the interpreting physician.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-11-14

The exact FDA decision document was reviewed on 2026-11-14 and reports no performance testing results for the subject device. Request the vendor's validation evidence.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for P160009. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Compatible GE Senoclaire digital breast tomosynthesis image data.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA P160009: PowerLook® Tomo Detection Software

  2. Routing

    Source context, not route validation: The reviewed iCAD conformance statement documents family-level DICOM exchange for PowerLook and Tomo Detection; exact P160009 interface versions require local confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA P160009: PowerLook® Tomo Detection Software

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: A CAD-enhanced synthetic two-dimensional image with detected soft-tissue densities blended for concurrent radiologist review and navigation to corresponding DBT planes.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA P160009: PowerLook® Tomo Detection Software

  5. Viewer/worklist/report

    Unresolved route: A CAD-enhanced synthetic two-dimensional image with detected soft-tissue densities blended for concurrent radiologist review and navigation to corresponding DBT planes.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA P160009: PowerLook® Tomo Detection Software

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The reviewed iCAD conformance statement documents family-level DICOM exchange for PowerLook and Tomo Detection; exact P160009 interface versions require local confirmation.
  • Exact FDA submission
  • Checked 2026-09-08
Security
iCAD's coordinated vulnerability disclosure statement commits to vulnerability intake via support@icadmed.com, confidential report handling, an evaluation response with an expected resolution date based on severity, progress updates to the reporter, and a safe-harbor commitment not to take legal action against reporters who follow the policy.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement on the iCAD owning domain (icadmed.com); the page banner notes iCAD is now part of DeepHealth, but the statement is iCAD's own product/system disclosure policy. No certification or audit report was read; exact-release scope is not established. Applicant name variant 'iCAD Inc' is bridged to iCAD, Inc. via the identical distinctive name and iCAD product naming.

Monitoring
iCAD's coordinated vulnerability disclosure statement states confidential intake, an evaluation response with a severity-based expected resolution date, and progress updates to the reporter.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The statement names iCAD generally and does not scope these commitments to any specific product release; exact-release scope is not established.

Current product-family workflow context

iCAD's PowerLook DICOM conformance statement documents the family-level DICOM objects and algorithm/version fields used by Tomo Detection workflows.

product family · checked 2026-09-08

Confirm exact-release availability, interfaces, hosting, security, support, and commercial terms during procurement.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
P160009
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
PMA
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2017-03-24
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-approved
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-08Last searched
18Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA scope controls clinical claims. ACR and official vendor material provide bounded catalog or product-family context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda pma approval page, vendor dicom conformance statement, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Evidence summary: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and reports no performance testing results for the subject device. Request the vendor's validation evidence.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact P160009 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 2 history items

Source ledger

  1. FDA P160009: PowerLook® Tomo Detection Software

    U.S. Food and Drug Administration - Published 2017-03-24 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  6. openFDA exact recall query for P160009

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  7. PowerLook DICOM conformance statement, revision E

    iCAD - Accessed 2026-09-08

    Scope: productFamily, DICOM, implementationCapabilities

  8. iCAD: Coordinated Vulnerability Disclosure Statement

    iCAD - Accessed 2026-10-27

    Scope: security

Research history

  1. P160009 FDA decision

    Regulatory record

    PMA

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23
FDA-cleared K253796

Lunit INSIGHT DBT (V1.2)

Lunit, Inc.

Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-03-26
FDA-cleared K243341

Genius AI Detection 2.0

Hologic, Inc.

Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-07-31

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history